TOKYO--(BUSINESS WIRE)--R-Tech Ueno, Ltd. (JASDAQ:4573): We are now pleased to announce the completion of Stage I of the Phase I/II clinical trial (hereinafter called this trial) of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101Note 1; hereafter RU-101 ophthalmic solution), which is being developed in our company, in the United States for the treatment of severe dry eye. RU-101 ophthalmic solution, and the commencement of enrollment for Stage II.
Help employers find you! Check out all the jobs and post your resume.
